Vector Manufacturing Market: Opinion Leaders Highlight Key Concerns

The growing pipeline of cell and gene therapies has led to an increase in demand for high-quality gene delivery vehicles and, therefore, has created significant opportunities for companies with expertise in manufacturing viral and non-viral vectors. In an article published last year, I discussed the growing cell and gene therapy market and how it has positively influenced the growth of the vector manufacturing market.

The current vector manufacturing landscape comprises of several players that claim to have the capability to develop vectors for cell and gene therapies. The infographic below summarizes the key facts associated with the vector contract manufacturing market.

vector manufacturing landscape

In a recent market research report, Roots Analysis interviewed several key stakeholders in the viral vector manufacturing market to understand the key challenges that the industry is currently facing.

In addition, the team conducted surveys with different players involved in the vector manufacturing space. The figure below summarizes the details of the players involved in the survey.

The key trends that the team unfolded in the discussions are highlighted below:

  1. Cost of manufacturing viral vectors is still significantly high
  2. There are several challenges associated with production output
  3. Stringent regulatory requirements exist for conducting human clinical trials
  4. The industry is facing concerns realted to final product contamination
  5. There is a need for changes in the operational models to sustain market growth
  6. The industry has witnessed a growing preference to outsource vector manufacturing operations
  7. Different players are constantly expanding capacity to accommodate for commercial scale operations
  8. This space has also seen the rise of spin offs/startups from the academic sector
  9. Some of the players are on the lookout for novel vectors based on transposons and sendai virus to address existing challenges
  10. Especially for contract manufacturers, there is a rising opportunity from late-stage genetically modified therapies
  11. Anticancer therapies presently contribute the most to the demand for vectors

The below-added infographic summarizes all the key challenges that the industry is currently facing:

Key Challenges in the Vector manufacturing market

The gene therapy, non viral vector and viral vector manufacturing market is estimated to be worth $891 million in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 10.49% during the forecast period 2023-2035.

The leading companies operating in this report are Advanced BioScience Laboratories, AGC Biologics, Aldevron, Altruist Biotechnology, BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech), BioReliance (a subsidiary of Merck KGaA), Biovian, Catalent Biologics, Celonic, Centre for Process Innovation, CEVEC Pharmaceuticals, Charles River Laboratories, CoJourney, Esco Aster, Jiangsu Puxin Biopharmaceutical, Lonza, Matica Biotechnology, Nikon CeLL innovation, NorthX Biologics, Novartis, Oxford BioMedica, Resilience, Sanofi, Thermo Fisher Scientific, VectorBuilder and Wuxi AppTec.

To know more about the growing, check out the report Viral Vector Manufacturing Market.